Edition:
India

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

41.00GBp
18 Apr 2019
Change (% chg)

0.93 (+2.32%)
Prev Close
40.07
Open
41.05
Day's High
41.69
Day's Low
40.10
Volume
10,622,168
Avg. Vol
5,357,627
52-wk High
504.60
52-wk Low
20.98

About

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue... (more)

Overall

Beta: --
Market Cap(Mil.): £2,498.61
Shares Outstanding(Mil.): 721.46
Dividend: --
Yield (%): --

Financials

  INDV.L Industry Sector
P/E (TTM): 48.23 29.30 32.55
EPS (TTM): 0.07 -- --
ROI: 25.75 14.23 13.83
ROE: -- 15.46 15.25

Indivior shares plummet, Reckitt hurt on U.S. charges over opioid prescriptions

(This April 10 story refiles to fix scrambled syntax in paragraph five)

11 Apr 2019

Indivior shares plummet, Reckitt hurt on U.S. charges over opioid prescriptions

British drugmaker Indivior Plc lost nearly three-quarters of its share value on Wednesday and former parent Reckitt Benckiser also fell following U.S. criminal charges accusing Indivior of illegally increasing prescriptions for its opioid addiction treatment Suboxone.

11 Apr 2019

REFILE-UPDATE 6-Indivior shares plummet, Reckitt hurt on U.S. charges over opioid prescriptions

* Indivior charged in the United States with conspiracy, fraud

11 Apr 2019

European stocks tick up post ECB decision, banks fall

European shares rose slightly on Wednesday as gains across most sectors offset losses among lenders, which were hit by a lack of detail in European Central Bank (ECB) comments after the bank left borrowing costs unchanged.

10 Apr 2019

UPDATE 2-European stocks tick up post ECB decision, banks fall

* Novartis among top healthcare losers after Morgan Stanley downgrades (Updates to close)

10 Apr 2019

U.S. indicts Indivior over Suboxone opioid treatment marketing

The U.S. Justice Department announced on Tuesday the indictment of Indivior Plc and a subsidiary on charges they engaged in an illegal scheme to boost prescriptions of the film version of its opioid addiction treatment Suboxone.

10 Apr 2019

UPDATE 3-U.S. indicts Indivior over Suboxone opioid treatment marketing

April 9 The U.S. Justice Department announced on Tuesday the indictment of Indivior Plc and a subsidiary on charges they engaged in an illegal scheme to boost prescriptions of the film version of its opioid addiction treatment Suboxone.

10 Apr 2019

U.S. indicts Indivior over Suboxone opioid treatment marketing

The U.S. Justice Department on Tuesday announced the indictment of Indivior Plc and a subsidiary on charges they engaged in an illegal scheme to boost prescriptions of the film version of its opioid addiction treatment Suboxone.

10 Apr 2019

Indivior launches generic version of its Suboxone opioid drug

British drugmaker Indivior Plc said on Wednesday it had launched a copycat version of its blockbuster opioid addiction drug Suboxone in the United States, just one day after a court decision cleared the way for its rivals to market generic versions of it.

20 Feb 2019

Indivior launches generic version of its Suboxone opioid drug

British drugmaker Indivior Plc said on Wednesday it had launched a copycat version of its blockbuster opioid addiction drug Suboxone in the United States, just one day after a court decision cleared the way for its rivals to market generic versions of it.

20 Feb 2019

Earnings vs. Estimates